Search results
Learn about the Risk Evaluation and Mitigation Strategy (REMS) programs for THALOMID, POMALYST and REVLIMID, which are administered by Bristol Myers Squibb. Find out how to enroll, comply and access the REMS programs as a prescriber, patient or pharmacy.
Learn how Celgene, a global biopharmaceutical company, is committed to improving the lives of patients worldwide by delivering truly innovative and life-changing treatments. Explore the therapies for Hematology, Oncology, Inflammation and Immunology and the medical research to help people live longer, better, and healthier.
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias.
- 1986; 37 years ago
- $15.281 billion (2018)
- 8,852 (2018)
People also ask
Is Celgene a pharmaceutical company?
What happened to Celgene common stock?
Who is Celgene?
Is Celgene a Bristol-Myers Squibb Company?
Nov 20, 2019 · NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and ...
Jan 3, 2019 · New York CNN Business —. Drugmaker Bristol-Myers Squibb announced Thursday a $74 billion deal to buy Celgene, in one of the biggest mergers in pharmaceutical industry history. The deal, which ...
- 3 min
Jan 3, 2019 · In connection with the proposed transaction between Bristol-Myers Squibb Company (“Bristol-Myers Squibb”) and Celgene Corporation (“Celgene”), Bristol-Myers Squibb and Celgene will file relevant materials with the Securities and Exchange Commission (the “SEC”), including a Bristol-Myers Squibb registration statement on Form S-4 that ...
Jan 4, 2019 · (Reuters) - Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, combining two of the world's largest cancer drug businesses in the biggest pharmaceutical...
